ArticleDigestive diseases and sciences2011
Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma.
Article in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer.Oncotarget · 2017Pooled it
- The prognostic and clinicopathologic characteristics of CD147 and esophagus cancer: A meta-analysis.PloS one · 2017Pooled it
- CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.Scientific reports · 2016Pooled it
- Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis.BioMed research international · 2015Pooled it
- EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival.BioMed research international · 2014Trial
- Cytoplasmic Basigin Localization is Associated with EMT, Tumor Budding, and Adverse Prognosis in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- CD147 at the crossroads of glycoprotein networks, metabolic reprogramming, and metastatic progression.Frontiers in immunology · 2025Review
- Role of CD147 in the development and diagnosis of hepatocellular carcinoma.Frontiers in immunology · 2023Review
- CD147 expression lacks prognostic relevance in esophageal cancer.Journal of cancer research and clinical oncology · 2022Article
- Pseudolaric Acid B Inhibits Proliferation, Invasion, and Angiogenesis in Esophageal Squamous Cell Carcinoma Through Regulating CD147.Drug design, development and therapy · 2020Article
- Expression of proteins associated with epithelial-mesenchymal transition in esophageal squamous cell carcinoma.Oncology letters · 2018Article
- CD147 expression was positively linked to aggressiveness and worse prognosis of gastric cancer: a meta and bioinformatics analysis.Oncotarget · 2017Article
- PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling.American journal of cancer research · 2016Article
- Expression of HAb18G in non-small lung cancer and characterization of activation, migration, proliferation, and apoptosis in A549 cells following siRNA-induced downregulation of HAb18G.Molecular and cellular biochemistry · 2013Article
- Prognostic significance of CD147 in patients with glioblastoma.Journal of neuro-oncology · 2013Article
- Expression of extracellular matrix metalloproteinase inducer and fascin in urinary bladder cancer: Correlation with clinicopathological characteristics.Molecular and clinical oncology · 2013Article
- EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer.Medical oncology (Northwood, London, England) · 2013Article
- The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?Technology in cancer research & treatmentReview
- Dual effects of an anti-CD147 antibody for Esophageal cancer therapy.Cancer biology & therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHAb18G/CD147 expression has been associated with many tumor invasion molecules, which play important roles in recurrence and poor differentiation of esophageal squamous cell carcinoma (ESCC). However, the clinical implications of HAb18G/CD147 in ESCC are still unclear.
aimsIn this study, we clarified the clinical significance of HAb18G/CD147 and characterized the association between HAb18G/CD147 and tumor invasion in ESCC cases.
methodsTumor tissues were obtained from 86 ESCC patients who underwent surgical resection between 2002 and 2005. All patients that had received previous therapy were excluded. ESCC tissues were analyzed by IHC using anti HAb18G/CD147 antibody. The expression of HAb18G/CD147 mRNA in esophageal cancer cell lines was analyzed by RT-PCR.
resultsHAb18G/CD147 was uniformly expressed in EC109 and EC871214 cell lines, but negatively expressed in EPC2, esophageal normal squamous cell line. HAb18G/CD147 mainly localized to the membrane of tumor cells in 84.9% of ESCC patients (64 out of 86 cases). Furthermore, we also found that higher HAb18G/CD147 expression levels significantly correlated with lymph node metastasis, depth of tumor invasion and differentiation (P < 0.05). But the expression levels of HAb18G/CD147 in lymph node metastatic tissues were almost equal to that in the primary tumor tissues. Furthermore, lymph node metastasis and expression of HAB18G/CD147 were independent prognostic indicators in ESCC.
conclusionsThe expression of HAb18G/CD147 might be involved in the progression and survival of ESCC. Therefore, HAb18G/CD147 could be a clinical marker for the poor prognosis in ESCC patients and may also be a potentially therapeutic target to improve the progression of ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.